BioVaxys Technology Corp.
BIOV
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.03M | -2.89M | -2.66M | -3.91M | -4.61M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.04M | 1.48M | 1.24M | 1.89M | 2.61M |
| Change in Net Operating Assets | -8.90K | 43.80K | 799.50K | 1.69M | 1.47M |
| Cash from Operations | -1.99M | -1.36M | -622.70K | -339.50K | -543.00K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -778.50K | -778.50K | -778.50K | -778.50K | -- |
| Cash from Investing | -778.50K | -778.50K | -778.50K | -778.50K | -- |
| Total Debt Issued | 0.00 | 0.00 | 13.80K | -- | -- |
| Total Debt Repaid | -33.40K | -33.40K | -33.40K | -33.40K | -- |
| Issuance of Common Stock | 3.05M | 3.16M | 2.41M | 1.68M | 1.63M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.18M | 2.30M | 1.76M | 1.22M | 1.21M |
| Foreign Exchange rate Adjustments | -3.80K | 1.70K | 1.10K | -2.00K | -3.00K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Net Change in Cash | -594.40K | 158.00K | 362.80K | 100.00K | 661.70K |